Peptide Injections Marketed as Anti-Aging Miracles Lack Any Rigorous Human Evidence, Exposing Users to Unregulated Risks

The Healthline report correctly flags the absence of credible safety data for compounded wellness peptides like BPC-157, TB-500, and CJC-1295, yet underplays how this mirrors the steroid era while ignoring deeper regulatory capture risks under HHS leadership. No randomized controlled trials (RCTs) exist in humans for these anti-aging or performance claims; available data are limited to small observational case series (n<50) or rodent models showing tissue repair signals that fail to translate due to dosing and bioavailability issues. The Institute for Safe Medication Practices position paper cited raises compounding pharmacy contamination alarms but omits conflict-of-interest analysis around influencer marketing, where paid promotions drive sales absent peer-reviewed backing. FDA oversight gaps parallel past anabolic steroid proliferation before the 1991 ban, yet RFK Jr.'s public peptide advocacy introduces potential policy reversal that could bypass even minimal state warnings like Alabama's. Experts such as Mandelbaum rightly label this an uninformed fad, but true analysis reveals systemic exploitation: users face unknown purity and cardiovascular or immune risks without any large-scale (n>500) longitudinal studies. Wellness peptides thus represent profit over evidence, draining wallets while health agencies lag.